Welcome to CenterNet's CME testing site for Recombinant Immunotoxin Therapy of Cancer: A Developing Alternative to Chemotherapy for Cancer and Autoimmune Diseases such as HIV.
This continuing educational activity consists of a 1 hour video with a CME post test and evaluation form.
This activity should take about 1.5 hours to complete. To qualify for credit and receive a Certificate of Completion, the participant should:
1. review the objectives
2. watch the video
3. complete the viewer evaluation, post test, and CME application which are all available online at this website.
If you achieve a score of 70% or more, you will be able to print your CME certificate from this online site.
If you don't manage to achieve a passing score, you are welcome to try again.
If you have any difficulty printing out your certificate, please email cme@centernet-tv.com with your problem.
CME credit is available until May 2004 for this program. No credit will be given after that date.
Good Luck!

Accreditation Information

The NIH/FAES is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The NIH/FAES designates this educational activity for a maximum of 1.5 hours in category 1 credit for each program (total of 15 hours for entire series) towards the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity.

     This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) and The Association of Academic Health Centers (AHC).  The views presented here are those of the Roundtable panel members and not necessarily those of CenterNet, the producer, the Association of Academic Health Centers, the National Cancer Institute of the National Institutes of Health, or any government agency. Neither the National Cancer Institute of the National Institutes of Health, nor any other government agency endorse any particular drug or product. Before using or prescribing any product discussed in the video, clinicians should consult the full prescribing information.

Objectives for Recombinant Immunotoxin Therapy of Cancer
• Identify two monoclonal antibodies now being used to treat cancer
• Describe why it is often necessary to attach a toxic substance to an antibody
• Understand the composition and basic structure of a recombinant immunotoxin.
• Be aware of which diseases have malignant cells which display surface CD22 or CD25 and which of these have responded best to recombinant immunotoxins
• Describe immunotoxin structure and composition
• Describe the pathway of immunotoxin killing of cancer cell.

Faculty Disclosures

Name

Grantee/Research

Consultant Speakers Bureau

Director

Stockholder/Optionee
Ira Pastan, M.D. 1,2,3 none none none
Robert J. Kreitman, M.D. none none none none
David Fitzgerald, Ph.D. 1 none none none
1.   Albapharm
2.   Neopharm
3.   Hoffman-LaRoche


 

 

CME Viewer Evaluation Form
Please complete the Continuing Medical Education online questionnaire.  The evaluation form provides each viewer the opportunity to rate the extent to which the educational objectives were met, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future education needs. To indicate your answers use the rating scale shown below by entering the number that represents your answer into the box to the right of each question. To move to the next question use your tab button. When you have completed the evaluation, please click on the "Take test" button at the bottom of the page.

1= none or not at all 2= very little 3= average 4= considerably 5= completely

1. Please rate the degree to which this program's objectives were attained:
• Identify two monoclonal antibodies now being used to treat cancer  
• Describe why it is often necessary to attach a toxic substance to an antibody
• Undestand the composition and basic structure of a recombinant immunotoxin
• Be aware of which diseases have malignant cells which display surface CD22 or CD25 and which of these have responded best to recombinant immunotoxins  
• Describe immunotoxin structure and composition
• Describe the pathway of immunotoxin killing of cancer cell

2. The quality of the instructional process was an asset to the program.

3. To what extent did participating in this activity enhance your professional effectiveness?

4. Please rate the quality of the graphics.

5. The instructions provided for the post test were clear and easy to follow.

6.  To what extent did the video: 
• Modify your opinion in this field?
• Modify your practice in this field?
• Reinforce your opinions in this field?
• Prepare you for your practice in this field?       

7.  Please rate the level of commercial bias in this educational activity.  

8.  Other topics you would like to see on video:

9.  Comments/suggestions:

Now that you have completed the evaluation, click below to take the test.